clinical trial

[MediciNova, Inc.] MediciNova, Inc. announced that the Phase II clinical trial of MN-166 in hospitalized COVID-19 patients at risk for developing acute respiratory distress syndrome has completed enrollment.

[SyneuRx™ International] SyneuRx™ International announced it has completed enrollment for its Phase II clinical trial evaluating the efficacy and safety of SNB01 ('Pentarlandir’), a novel COVID-19 oral antiviral candidate.

[Neuro-Oncology] Researchers screened a library of drugs either FDA-approved or in clinical trial using a library of patient-derived H3K27M-mutant diffuse midline glioma cell lines with cell viability as the outcome.

[SELLAS Life Sciences Group, Inc.] SELLAS Life Sciences Group, Inc. announced that the first acute myeloid leukemia patient has enrolled in the fifth dose level cohort, out of the expected six dose cohorts, in the ongoing Phase I dose-escalating clinical trial with SELLAS’ newly in-licensed GFH009 asset.

[Nature Medicine] Investigators administered a recombinant bicistronic adeno-associated virus (AAV8) vector coding for both the light and heavy chains of the potent broadly neutralizing HIV-1 antibody VRC07 to eight adults living with HIV.

[Nature Communications] The authors showed that broadening the number of neoantigen-reactive CD8+ T cell populations between pre-treatment to three weeks post-treatment distinguished patients with controlled disease compared to patients with progressive disease in metastatic urothelial carcinoma treated with PD-L1-blockade.